Clinical Trial Update: A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation safety study of locally-delivered gemcitabine in pancreatic cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (locally-delivered) (gemcitabine)

Snippet

Sponsor: RenovoRx | Conditions: Pancreatic Cancer | Phase 1 | Status: COMPLETED | Results posted: 2021-05-07